Matches in Wikidata for { <http://www.wikidata.org/entity/Q91682322> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q91682322 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q91682322 description "im April 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91682322 description "scientific article published on 17 April 2019" @default.
- Q91682322 description "wetenschappelijk artikel" @default.
- Q91682322 description "наукова стаття, опублікована 17 квітня 2019" @default.
- Q91682322 name "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 name "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 type Item @default.
- Q91682322 label "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 label "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 prefLabel "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 prefLabel "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 P1433 Q91682322-75A35B71-DE93-4F39-8E8A-14983227C8C0 @default.
- Q91682322 P1476 Q91682322-24A43030-1EEE-4985-B64B-88BAB9DDB7BD @default.
- Q91682322 P2093 Q91682322-41244416-9810-48C9-A5CD-142BCAB8236A @default.
- Q91682322 P2093 Q91682322-A9E5817E-BB2B-4AF2-A9EE-17A03A551794 @default.
- Q91682322 P2093 Q91682322-B8330CD7-6D7A-4F07-82AF-3F29D611B3FE @default.
- Q91682322 P2093 Q91682322-D099539A-8F72-4D07-B253-59A6ACD3EA7A @default.
- Q91682322 P304 Q91682322-F703D636-E1FF-4099-942D-EA9CE0BE49C6 @default.
- Q91682322 P31 Q91682322-0434ADDB-9F60-4ADE-90E4-AD1F702E9ED8 @default.
- Q91682322 P31 Q91682322-bbfa4b3e-6019-4d52-8a6c-49cf13f6f1b3 @default.
- Q91682322 P356 Q91682322-47FEF101-F8AC-4755-8114-4BD45DE529EA @default.
- Q91682322 P433 Q91682322-EFA6BBE2-F313-456B-9A60-B81BD916D56E @default.
- Q91682322 P478 Q91682322-CDD90F4C-7CA2-4B6E-9D72-D8DFD82F5640 @default.
- Q91682322 P577 Q91682322-C9B1A2AC-79F2-4279-B98D-4CE02EB04720 @default.
- Q91682322 P698 Q91682322-87765C67-34FD-46B4-B541-8E2C2C446676 @default.
- Q91682322 P921 Q91682322-79213A9B-527B-492A-BEFD-E2466EE6DD37 @default.
- Q91682322 P356 CCO.2019.02.06 @default.
- Q91682322 P698 31280572 @default.
- Q91682322 P1433 Q27724839 @default.
- Q91682322 P1476 "Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe" @default.
- Q91682322 P2093 "Adam Garsa" @default.
- Q91682322 P2093 "Chaosu Hu" @default.
- Q91682322 P2093 "Eric L Chang" @default.
- Q91682322 P2093 "Jennifer C Ho" @default.
- Q91682322 P304 "S20" @default.
- Q91682322 P31 Q13442814 @default.
- Q91682322 P31 Q871232 @default.
- Q91682322 P356 "10.21037/CCO.2019.02.06" @default.
- Q91682322 P433 "S1" @default.
- Q91682322 P478 "8" @default.
- Q91682322 P577 "2019-04-17T00:00:00Z" @default.
- Q91682322 P698 "31280572" @default.
- Q91682322 P921 Q413299 @default.